中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

48 records (took 0.025 seconds)

    MOS STRUCTURES THAT EXHIBIT LOWER CONTACT RESISTANCE AND METHODS FOR FABRICATING THE SAME
    12.
    发明申请
    MOS STRUCTURES THAT EXHIBIT LOWER CONTACT RESISTANCE AND METHODS FOR FABRICATING THE SAME 审中-公开
    具有较低接触电阻的MOS结构及其制造方法

    公开(公告)号：WO2009025706A1

    公开(公告)日：2009-02-26

    申请号：PCT/US2008/008801

    申请日：2008-07-18

    Applicant: ADVANCED MICRO DEVICES, INC. ,  BALASUBRAMANIAN, Sriram

    Inventor： BALASUBRAMANIAN, Sriram

    IPC: H01L21/285 ,  H01L21/336 ,  H01L23/485

    CPC classification number: H01L21/28525 ,  H01L21/28518 ,  H01L23/485 ,  H01L29/41725 ,  H01L29/41775 ,  H01L29/41783 ,  H01L29/6656 ,  H01L2924/0002 ,  H01L2924/00

    Abstract: MOS structures (100, 200) that exhibit lower contact resistance and methods for fabricating such MOS structures are provided. In one method, a semiconductor substrate (106) is provided and a gate stack (146) is fabricated on the semiconductor substrate. An impurity-doped region (116) within the semiconductor substrate aligned with the gate stack is formed. Adjacent contact fins (186) extending from the impurity-doped region are fabricated and a metal suicide layer (126) is formed on the contact fins. A contact (122) to at least a portion of the metal suicide layer on at least one of the contact fins is fabricated.

    Abstract translation: 提供具有较低接触电阻的MOS结构（100,200）和制造这种MOS结构的方法。 在一种方法中，提供半导体衬底（106）并且在半导体衬底上制造栅叠层（146）。 形成与栅叠层对准的半导体衬底内的杂质掺杂区（116）。 制造从杂质掺杂区域延伸的相邻接触翅片（186），并在接触翅片上形成金属硅化物层（126）。 制造了至少一个接触翅片上的金属硅化物层的至少一部分的接触（122）。

    METHODS FOR DETERMINING CANCER RESISTANCE TO HISTONE DEACETYLASE INHIBITORS
    15.
    发明申请
    METHODS FOR DETERMINING CANCER RESISTANCE TO HISTONE DEACETYLASE INHIBITORS 审中-公开
    用于确定抗组氨酸脱乙酰酶抑制剂的耐药性的方法

    公开(公告)号：WO2008095050A1

    公开(公告)日：2008-08-07

    申请号：PCT/US2008/052540

    申请日：2008-01-30

    Applicant: PHARMACYCLICS, INC. ,  BUGGY, Joseph, J. ,  BALASUBRAMANIAN, Sriram

    Inventor： BUGGY, Joseph, J. ,  BALASUBRAMANIAN, Sriram

    IPC: A61K49/00 ,  C12Q1/68 ,  G01N33/574

    CPC classification number: C12Q1/6886 ,  C07H21/04 ,  C12N5/0693 ,  C12N15/11 ,  C12N2503/02 ,  C12Q2600/106 ,  C12Q2600/112 ,  C12Q2600/136 ,  C12Q2600/158 ,  C12Q2600/16 ,  G01N33/57419 ,  G01N33/57492 ,  G01N2800/52

    Abstract: [00153] Described herein are methods and compositions for determining whether a particular cancer is resistant to or susceptible to a histone deacetylase inhibitor or to histone deacetylase inhibitors. The methods include analysis of the expression levels of at least four biomarker genes associated with response to a histone deacetylase inhibitor. Also described herein are methods and compositions for increasing the likelihood of a therapeutically effective treatment in a patient, comprising an analysis of the expression levels of at least four biomarker genes associated with response to a histone deacetylase inhibitor. Also described herein are isolated populations of nucleic acids derived from a cancer sensitive to or resistant to a histone deacetylase inhibitor. Further described are kits and indications that are used in conjunction with the aforementioned methods and compositions.

    Abstract translation: 本文描述了用于确定特定癌症是否对组蛋白脱乙酰酶抑制剂或组蛋白脱乙酰酶抑制剂具有抗性或易感性的方法和组合物。 所述方法包括分析与对组蛋白脱乙酰酶抑制剂的反应相关的至少四种生物标记基因的表达水平。 本文还描述了用于增加患者治疗有效治疗可能性的方法和组合物，包括与对组蛋白脱乙酰酶抑制剂的反应相关的至少四种生物标记基因的表达水平的分析。 本文还描述了衍生自对组蛋白脱乙酰酶抑制剂敏感或抗性的癌症的分离的核酸群体。 进一步描述了与上述方法和组合物结合使用的试剂盒和适应症。

    USES OF SELECTIVE INHIBITORS OF HDAC8 FOR TREATMENT OF T-CELL PROLIFERATIVE DISORDERS
    16.
    发明申请
    USES OF SELECTIVE INHIBITORS OF HDAC8 FOR TREATMENT OF T-CELL PROLIFERATIVE DISORDERS 审中-公开
    HDAC8选择性抑制剂用于治疗T细胞增殖性疾病的用途

    公开(公告)号：WO2008060721A1

    公开(公告)日：2008-05-22

    申请号：PCT/US2007/073802

    申请日：2007-07-18

    Applicant: PHARMACYCLICS, INC. ,  BUGGY, Joseph, J. ,  BALASUBRAMANIAN, Sriram

    Inventor： BUGGY, Joseph, J. ,  BALASUBRAMANIAN, Sriram

    IPC: A61K31/535

    CPC classification number: C12Q1/34 ,  A61K31/535 ,  G01N33/57426 ,  G01N2333/918 ,  G01N2800/52

    Abstract: Described herein are methods for treating a subject suffering from a T-cell lymphoma by administering to the subject a pharmaceutical composition containing a therapeutically effective amount of a selective inhibitor of histone deacetylase 8. Also described herein are methods for treating a subject suffering from a T-cell lymphoma by administering to the subject a population of autologous T-cells that have been exposed to a selective HDAC8 inhibitor composition ex vivo .

    Abstract translation: 本文描述的是通过向受试者施用含有治疗有效量的组蛋白脱乙酰酶8的选择性抑制剂的药物组合物来治疗患有T细胞淋巴瘤的受试者的方法。本文还描述了治疗患有T细胞的受试者的方法 细胞淋巴瘤，其通过向受试者施用已经离体地暴露于选择性HDAC8抑制剂组合物的自体T细胞群体。

Patent Agency Ranking